Document Detail

Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
MedLine Citation:
PMID:  23322007     Owner:  NLM     Status:  MEDLINE    
Vaccines have had a major role in enhancing the quality of life and increasing life expectancy. Despite these successes and the development of new vaccine technologies, there remain multiple infectious diseases including AIDS, malaria and tuberculosis that require effective prophylactic vaccines. New and traditional technologies have a role in the development and delivery of the new vaccine candidates. The scientific challenges, opportunities and funding models for developing vaccines for low resource settings are highlighted here.
Sonali Kochhar
Related Documents :
23246547 - Vectored co-delivery of human cytomegalovirus gh and gl proteins elicits potent complem...
24315427 - Papillomavirus vaccination in france according to 2008 to 2012 vaccinoscopie(®) data.
2326707 - Relation between form and function in the sacroiliac joint. part ii: biomechanical aspe...
23406827 - Prospects for prophylactic hepatitis c vaccines based on virus-like particles.
22284787 - Rotavirus diversity and evolution in the post-vaccine world.
24441177 - Formulation of newcastle disease virus coupled calcium phosphate nanoparticles: an effe...
Publication Detail:
Type:  Congresses     Date:  2013-01-15
Journal Detail:
Title:  Human vaccines & immunotherapeutics     Volume:  9     ISSN:  2164-554X     ISO Abbreviation:  Hum Vaccin Immunother     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-10-04     Completed Date:  2014-04-21     Revised Date:  2014-10-09    
Medline Journal Info:
Nlm Unique ID:  101572652     Medline TA:  Hum Vaccin Immunother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  928-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Capital Financing / organization & administration*
Developing Countries
Drug Discovery / economics*,  methods*
Technology, Pharmaceutical / economics*,  methods*
Vaccines / economics*,  isolation & purification*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular Modeling Comparison of the Performance of NS5b Polymerase Inhibitor (PSI-7977) on Prevalen...
Next Document:  A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant tran...